Large-scale external validation and comparison of prognostic models

Guerra, Beniamino; Soriano, Joan; haile, sarah; Lamprecht, Bernd; Ramirez, Ana; Turner, Alice; Martinez-Camblor, Pablo; Kaiser, Bernhard; Alfageme, Inmaculada; Almagro, Pere; Casanova, Ciro; Soler-Cataluna, Juan; de-Torres, Juan P; Miravitlles, Marc; Celli, Bartolome; Ter Riet, Gerben; Marin, Jose M; Sobradillo, Patricia; González-Estévez, Cristina; Garcia-Aymerich, Judith

DOI: 10.1186/s12916-018-1013-y

License: Creative Commons: Attribution (CC BY)

Citation for published version (Harvard):
Guerra, B, Soriano, J, haile, S, Lamprecht, B, Ramirez, A, Turner, A, Martinez-Camblor, P, Kaiser, B, Alfageme, I, Almagro, P, Casanova, C, Soler-Cataluna, J, de-Torres, JP, Miravitlles, M, Celli, B, Ter Riet, G, Marin, JM, Sobradillo, P, Gonzalez-Estévez, C, Garcia-Aymerich, J, Langer, B, Han, MK, Langhammer, A, Leivseth, L, Bakke, P, Oga, T, Johanessen, JO, Cosio, B, Roche, N, Ancochea, J, Burgel, P-R, Sin, D & Puhan, M 2018, 'Large-scale external validation and comparison of prognostic models: An application to chronic obstructive pulmonary disease', BMC medicine, vol. 16, 33. https://doi.org/10.1186/s12916-018-1013-y

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 10. Mar. 2020
Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease

Beniamino Guerra 1, Sarah R. Haile 1, Bernd Lamprecht 2,3, Ana S. Ramírez 4, Pablo Martinez-Camblor 5, Bernhard Kaiser 6, Inmaculada Alfageme 7, Pere Almagro 8, Ciro Casanova 9, Cristóbal Esteban-González 10, Juan J. Soler-Cataluña 11, Juan P. de-Torres 12, Marc Miravitlles 13, Bartolome R. Celi 14, Jose M. Marín 15, Gerben ter Riet 16, Patricia Sobradillo 17, Peter Lange 18, Judith García-Aymerich 19, Josep M. Antó 20, Alice M. Turner 21, Meilan K. Han 22, Arnulf Langhammer 23, Linda Leivseth 24, Per Bakke 25, Ane Johannessen 26, Toru Oga 27, Borja Cosío 28, Julio Ancochea-Bermúdez 29, Andres Echazarreta 30, Nicolas Roche 31, Pierre-Régis Burgel 32, Don D. Sin 33, Joan B. Soriano 34,35, Milo A. Puhani 36,37 and for the 3CIA collaboration

Abstract

Background: External validations and comparisons of prognostic models or scores are a prerequisite for their use in routine clinical care but are lacking in most medical fields including chronic obstructive pulmonary disease (COPD). Our aim was to externally validate and concurrently compare prognostic scores for 3-year all-cause mortality in mostly multimorbid patients with COPD.

Methods: We relied on 24 cohort studies of the COPD Cohorts Collaborative International Assessment consortium, corresponding to primary, secondary, and tertiary care in Europe, the Americas, and Japan. These studies include globally 15,762 patients with COPD (1871 deaths and 42,203 person years of follow-up). We used network meta-analysis adapted to multiple score comparison (MSC), following a frequentist two-stage approach; thus, we were able to compare all scores in a single analytical framework accounting for correlations among scores within cohorts. We assessed transitivity, heterogeneity, and inconsistency and provided a performance ranking of the prognostic scores.

Results: Depending on data availability, between two and nine prognostic scores could be calculated for each cohort. The BODE score (body mass index, airflow obstruction, dyspnea, and exercise capacity) had a median area under the curve (AUC) of 0.679 [1st quartile–3rd quartile = 0.655–0.733] across cohorts. The ADO score (age, dyspnea, and airflow obstruction) showed the best performance for predicting mortality (difference AUCADO – AUCBODE = 0.015 [95% confidence interval (CI) = −0.002 to 0.032]; p = 0.08) followed by the updated BODE (AUCBODE updated – AUCBODE = 0.008 [95% CI = −0.005 to +0.022]; p = 0.23). The assumption of transitivity was not violated. Heterogeneity across direct comparisons was small, and we did not identify any local or global inconsistency.

(Continued on next page)
Conclusions: Our analyses showed best discriminatory performance for the ADO and updated BODE scores in patients with COPD. A limitation to be addressed in future studies is the extension of MSC network meta-analysis to measures of calibration. MSC network meta-analysis can be applied to prognostic scores in any medical field to identify the best scores, possibly paving the way for stratified medicine, public health, and research.

Keywords: COPD, Prognostic scores, Large-scale external validation, Performance comparison, Network meta-analysis

Background
Prognostic scores, commonly based on coefficients from regression models, provide a probability of a certain adverse outcome for an individual over a specified time horizon. Prognostic scores have become increasingly popular over the last two decades [1–5]. They serve multiple purposes such as informing individuals and health care providers about disease and outcome risks, supporting risk-stratified and personalized prevention or treatment decisions, identifying participants for research, or adjusting for confounding [6–9].

Numerous prognostic models have been developed in various fields of medicine [10–13]. Just for predicting the risk of cardiovascular disease in the general population, a recent review identified 363 prognostic models or scores [14]. For patients with chronic obstructive pulmonary disease (COPD), prognostic scores have been developed mostly to predict the risk of death [15–30], but scores also exist to predict exacerbations [31] or deteriorating of health-related quality of life [27, 32].

Major obstacles for using prognostic scores in practice and research are, however, the frequent lack of external validations, comparisons of their predictive performance, and assessments of their applicability in practice [2, 33–38]. Practitioners and researchers are left with uncertainty about which prognostic score to use and may be reluctant to use them at all [39]. Ideally, prognostic scores would be externally validated in several different populations and their performance summarized [40, 41]. However, such external validations and concurrent comparisons are rarely performed [42]. In addition, for even more comprehensive comparison, the performance of prognostic scores may be compared indirectly using common comparator scores similar to network meta-analysis (NMA) [43–48] of randomized trials.

Our aim was to use multiple score comparison (MSC) in order to externally validate and concurrently compare prognostic scores for 3-year mortality in patients with COPD.

Methods
We followed a prespecified study protocol and described the detailed statistical methods elsewhere [43].

Study design and participants
This study was based on 26 cohort studies of the COPD Cohorts Collaborative International Assessment (3CIA) consortium. Details have been reported elsewhere (and summarized in Table 2) [49]. All cohorts were approved by ethics committees, and participants gave written informed consent [49]. We also included the Phenotype and Course (PAC)-COPD and Copenhagen cohorts in the final database, even if they were used in the large-scale update of the ADO (age, dyspnea, and airflow obstruction) index [15]. We considered this approach reasonable, since they form only a small part of the final database, but we verified in a sensitivity analysis if they affected the results.

Prognostic scores
Starting from the literature review of two studies [32, 42] and searching among their references, PubMed-related articles, and through our research network, we identified 19 prognostic scores, of which we included 10 in our analysis. The scores (see Table 1 for details) were the BODE (body mass index, airflow obstruction, dyspnea, and severe exacerbations) [17], updated BODE [16], ADO (we included in the analysis only the updated ADO index and not the original ADO index [16] because the updated ADO was generated from large-scale external validation; however, we will name it simply ADO) [15], eBODE (severe acute exacerbation of COPD plus BODE) [18], BODEX (body mass index, airflow obstruction, dyspnea, severe acute exacerbation of COPD) [18], DOSE (dyspnea, obstruction, smoking and exacerbation frequency) [27], SAFE (Saint George’s Respiratory Questionnaire (SGRQ) score, airflow limitation and exercise capacity) [28], and B-AE-D (body mass index, acute exacerbations, dyspnea; we used the optimized version and not the original B-AE-D score) [23]. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification [50, 51] and the 2011–2016 GOLD classification (often referred to as new GOLD in the recent COPD literature) [51] were also used in the analysis, even if they were not designed for prognostic purposes. Apart from original ADO and original B-AE-D score the other seven identified scores from the literature were excluded from the analysis, since our database did not include at least one of their predictors or did not include them simultaneously in at least one cohort.
Table 1 Scoring rules of prognostic scores to predict mortality in patients with COPD

| Score Predictor | GOLD [50, 51] | GOLD (2011–2016) [51] | BODE [17] | BODE upd. [16] | ADO [15] | e-BODE [18] | BODEx [18] | DOSE [27] | SAFE [28] | B-AE-D [23] |
|----------------|----------------|------------------------|-----------|----------------|----------|-------------|-----------|-----------|-----------|-------------|
| BMI            | 0 (> = 21)     | 0 (> = 21)             | 0 (> = 21)| 0 (> = 21)    | 0 (> = 21)| 0 (> = 21) | 0 (> = 21)| 0 (> = 21)| 0 (> = 21)| 6 (185–21)  |
|                | 1 (< = 21)     | 1 (< = 21)             | 1 (< = 21)| 1 (< = 21)    | 1 (< = 21)| 1 (< = 21) | 1 (< = 21)| 1 (< = 21)| 1 (< = 21)| 9 (< = 185)  |
| FEV1% pred.   | 0 (> = 80%)    | 0 (> = 85%)            | 0 (> = 81%)| 0 (> = 65%)   | 0 (> = 65%)| 0 (> = 50%)| 0 (> = 80%)| 0 (> = 80%)| 0 (> = 80%)| 0 (> = 80%)  |
|                | 1 (50–79%)     | 1 (50–64%)             | 1 (50–64%)| 1 (50–64%)    | 1 (50–64%)| 1 (31–49%)  | 1 (50–79%)| 1 (50–79%)| 1 (50–79%)| 1 (50–79%)  |
|                | 2 (30–49%)     | 2 (36–49%)             | 2 (36–49%)| 2 (36–49%)    | 2 (36–49%)| 2 (36–49%)  | 2 (36–49%)| 2 (36–49%)| 2 (36–49%)| 2 (36–49%)  |
|                | 3 (< 30%)      | 3 (< 35%)              | 3 (< 35%) | 3 (< 35%)     | 3 (< 35%) | 2 (< 35%)   | 3 (< 35%) | 3 (< 35%)| 3 (< 35%)| 3 (< 35%)   |
|                |                |                        |           |               |          |             |           |           |           |             |
| mMRC           | 0 (if mMRC > = 2 and CAT > = 10) | 0 (0–1)     | 0 (0–1)    | 0 (0–1)       | 0 (0–1)  | 0 (0–1)     | 0 (0–1)  | 0 (0–1) | 0 (0–1) | 0 (0–1)     |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
| 1 other wise   | 1 (2)          | 1 (2)                  | 1 (2–3)   | 1 (2)         | 1 (2)    | 1 (2–3)     | 1 (2)    | 1 (2)   | 1 (2)   | 1 (2)       |
|                | 2 (3)          | 2 (3)                  | 2 (3)     | 2 (3)         | 2 (3)    | 2 (3)       | 2 (3)   | 2 (3)   | 2 (3)   | 2 (3)       |
|                | 3 (4)          | 3 (4)                  | 3 (4)     | 3 (4)         | 3 (4)    | 3 (4)       | 3 (4)   | 2 (2)   | 2 (2)   | 2 (2)       |
| 6MWT (m)       | 0 (> = 350)    | 0 (> = 350)            | 0 (> = 350)| 0 (> = 350)  | 0 (> = 350)| 0 (> = 350)| 0 (> = 350)| 0 (> = 350)| 0 (> = 350)| 0 (> = 350)  |
|                | 1 (250–349)    | 1 (250–349)            | 1 (250–349)| 1 (250–349)  | 1 (250–349)| 1 (250–349)| 1 (250–349)| 1 (250–349)| 1 (250–349)| 1 (250–349)  |
|                | 2 (150–249)    | 2 (150–249)            | 2 (150–249)| 2 (150–249)  | 2 (150–249)| 2 (150–249)| 2 (150–249)| 2 (150–249)| 2 (150–249)| 2 (150–249)  |
|                | 3 (< = 149)    | 3 (< = 149)            | 3 (< = 149)| 3 (< = 149)  | 3 (< = 149)| 3 (< = 149)| 3 (< = 149)| 3 (< = 149)| 3 (< = 149)| 3 (< = 149)  |
| Age (years)    |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                | 0 (40–49)      |                        |          |               |          |             |           |           |           |             |
|                | 2 (50–59)      |                        |          |               |          |             |           |           |           |             |
|                | 4 (60–69)      |                        |          |               |          |             |           |           |           |             |
|                | 5 (70–79)      |                        |          |               |          |             |           |           |           |             |
|                | 7 (> = 80)     |                        |          |               |          |             |           |           |           |             |
| Prev. exacerbation | (See FEV1pp)   | 0 (0)                  | 0 (0)    | 0 (0–1)       | 0 (0)   | 1 (1–2)    | 1 (1–2) | 1 (1–2) | 1 (1–2) | 3 (1)       |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
| CAT            | (See mMRC)     | 0 (0)                  | 0 (0)    | 0 (0–1)       | 0 (0)   | 1 (1–2)    | 1 (1–2) | 1 (1–2) | 1 (1–2) | 3 (1)       |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
| Smoking        | (See FEV1pp)   | 0 (non-smoker)         |          |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
|                |                |                        |           |               |          |             |           |           |           |             |
### Table 1: Scoring rules of prognostic scores to predict mortality in patients with COPD (Continued)

| Score Predictor | GOLD [50, 51] | GOLD (2011–2016) [51] | BODE [17] | BODE upd. [16] | ADO [15] | e-BODE [18] | BODEx [18] | DOSE [27] | SAFE [28] | B-AE-D [23] |
|-----------------|----------------|------------------------|-----------|---------------|---------|------------|------------|-----------|----------|-----------|
| Quality of life (SGRQ) | 0 (<= 30) | 1 (31–49) | 2 (50–64) | 3 (> = 65) | 0–3 | 0–3 | 0–10 | 0–15 | 0–14 | 0–12 | 0–9 | 0–8 | 0–9 | 0–26 |

**Total score**

| 0–3 | 0–3 | 0–10 | 0–15 | 0–14 | 0–12 | 0–9 | 0–8 | 0–9 | 0–26 |

**Abbreviations:**
- BMI: body mass index
- FEV1% pred.: forced expiratory volume in 1 s percentage predicted
- mMRC: modified Medical Research Council dyspnea scale
- 6MWT: 6-min walk test
- CAT COPD: Assessment Test
- SGRQ: Saint George’s Respiratory Questionnaire
- Previous exacerbations are referred to the previous year
- GOLD: Global Initiative for Chronic Obstructive Lung Disease
- BODE: body mass index, airflow obstruction, dyspnea, and severe exacerbations
- BODE upd.: BODE updated
- ADO: age, dyspnea, airflow obstruction (we use in our analysis the updated version of the ADO score)
- e-BODE: severe acute exacerbation of COPD plus BODE
- BODEx: body mass index, airflow obstruction, dyspnea, severe acute exacerbation of COPD, DOSE: dyspnea, obstruction, smoking, and exacerbation frequency
- SAFE: Saint George’s Respiratory Questionnaire (SGRQ) score, airflow limitation and exercise capacity
- B-AE-D: body mass index, acute exacerbations, dyspnea (we use the optimized version of the score introduced in the same paper)

Missing cells correspond to variables that do not constitute the score of the correspondent column.
Outcome and performance measure for external validation and comparison of prognostic scores

We evaluated a number of performance measures commonly used to assess the prognostic properties of prediction models and scores [43]. We deemed the area under the curve (AUC) to be the most appropriate performance measure for our purposes, mainly because its range is independent of the data, it is easy to interpret, and an analytic formula for its variance is available [52].

Statistical analysis

We followed a prespecified study protocol. We first performed direct head-to-head comparisons using random effects meta-analysis and then examined the network evidence merging all available direct and indirect evidence [53]. We used a novel methodology, i.e., MSC meta-analysis, adapted from multiple treatment comparison network meta-analysis [54, 55]. Methodological details are reported in the section “Detailed Methods” in Additional file 1 and in a recent paper [43]. R codes are available (provided in the section “R Code for MSC meta-analysis” in Additional file 1).

Direct comparisons (random effects pairwise meta-analysis)

We directly compared prognostic scores by pairwise random effects meta-analysis [56, 57]. We used forest plots to visually investigate statistical heterogeneity as well as the $I^2$ statistic. Such standard meta-analysis has limitations, since it does not take into account the correlations among multiple scores evaluated on the same set of patients [58], and it does not give a clear indication of which prognostic score performs best. Thus, we adopted network meta-analysis, an approach that allowed us to weight and then pool the results coming from different cohorts.

MSC meta-analysis

Methodological details are reported in detail in [43]. In brief, we used an example of implementation of network meta-analysis for treatment effectiveness comparison [54], adapting it to our purposes, namely to concurrently validate and compare prognostic scores from individual patient data across different cohorts [43]. We have explicitly included correlations [58] between the scores on a cohort level. We use a frequentist two-stage meta-regression model, as proposed in [54]:

1. Ordinary meta-analysis (stage I) to obtain the direct estimates for pooled differences in AUC (using the inverse-variance weighted means of the corresponding cohorts). The meta-analyses were done within each group of cohorts where data for the same prognostic scores were available.

2. In stage II, we merged the estimates for the differences in AUC from the groups of cohorts, looking for the weighted least squares solution to the regression problem equation. Based on the direct estimates and their variances from the first stage, we estimated the pooled differences in AUC that obeyed fundamental consistency equations. Thus in stage II, the stage I estimates for the differences in AUC were combined across groups of cohorts to give overall performance estimates for the entire network.

In order to provide a ranking of the scores, we used a frequentist version of the surface under the cumulative ranking curve (SUCRA) [59, 60] score showing the likelihood of the score to be better than any other score and summarizing relative performances and confidence intervals.

The last steps were to ensure that the heterogeneity, transitivity, and consistency assumptions were met [46]. Heterogeneity in the MSC analysis was evaluated by the pooled heterogeneity variance among groups ($\tau_{pooled}^2$). We assessed “transitivity” through analysis of variance (ANOVA) tests. Thus, we assessed the comparability of the cohorts across whom the predictive performance of a score may vary because of a “spectrum effect” [61] or “case mix” [37, 62, 63]. We also assessed consistency [46] between direct evidence and MSC meta-analysis estimates using the Q likelihood-ratio test statistic to evaluate the global consistency and analysis of residuals and leverages to evaluate the local consistency [54]. For more details, see “Detailed Methods” in Additional file 1 and [43].

Handling of missing data

If a variable was missing for >30% of the patients, we discarded the specific variable for that particular specific cohort, since the effects of such predictors could be generally distrusted [1]. Otherwise we performed multiple imputation with chained equations (the analysis of the patterns of missingness allowed us to consider the missing data missing completely at random apart from the dependence on the cohort) [4]. We combined the estimates of the 30 different analyses (one for each imputed dataset, for each of which we followed all the previously highlighted frequentist two-stage meta-regression model approaches) using Rubin’s rules.

Results

Cohort and participant characteristics

The cohorts varied greatly in terms of geographic location, sample size, and number of events and included a broad spectrum of patients with COPD from primary, secondary, and tertiary care settings (Table 2). Mean forced expiratory volume in 1 s percentage (FEV1) ranged from 30 to 70% of the predicted values, mean modified Medical Research Council (mMRC) dyspnea scores from

...
### Table 2  Study characteristics

| Cohort          | Number of Events | Number of patients | Person years | Mean age, years | Men, % | Mean FEV1%pred. | Mean mMRC | Past exacerbators, % | Mean no. prev. exacerbations | Current smoker, % | Mean BMI | Mean 6MWT, m | Mean SGRQ | Mean CAT |
|-----------------|------------------|--------------------|--------------|-----------------|--------|------------------|-----------|--------------------|-------------------------------|------------------|----------|--------------|-----------|----------|
| COPDgene        | 337              | 4484               | 10,003       | 63 (9)          | 56     | 57.4 (22.8)      | 1.5       | 0.16               | 43               | 27.9 (6.1)      | 37.1 (14.1) | 36.9 (22.9) |
| Sevillea a      | 205              | 596                | 1562         | 66 (10)         | 95     | 43.5 (13.3)      | 1         | 0.25               | 1.16             | 29.2 (5.7)      |
| Copenhagen b    | 186              | 2287               | 6618         | 61 (9)          | 54     | 70.5 (23.7)      | 1.3       | 71                 | 25.4 (4.2)       |
| Genkols         | 126              | 954                | 2708         | 65 (10)         | 61     | 46.9 (17.7)      | 1.3       | 0.6                | 47               | 25.4 (5)       |
| Zaragoza III b  | 118              | 1150               | 3069         | 63 (9)          | 93     | 62.3 (20.3)      | 1.1       | 0.17               | 0.91             | 34               | 27.5 (4.8) | 356.2 (153.7) |
| HUNT            | 116              | 1571               | 4583         | 63 (13)         | 62     | 63.8 (18.7)      | 1.3       | 47                 | 26.4 (4.4)       |
| Galdakao a      | 92               | 543                | 1497         | 68 (8)          | 96     | 55.1 (13.3)      | 0.9       | 0.65               | 21               | 28.3 (4.4) | 408.9 (92.4) |
| Barcinska b     | 79               | 232                | 555          | 72 (9)          | 60     | 45.2 (16.1)      | 1.1       | 24                 | 26.6 (3.3)       | 363.4 (126.8) |
| Terrassa III b  | 78               | 181                | 423          | 72 (10)         | 95     | 45.2 (14.4)      | 1.2       | 0.31               | 1.28             | 23               | 27.9 (5) | 330.4 (105.8) |
| Initiatives BPCO| 76               | 930                | 1525         | 64 (10)         | 77     | 52.4 (20.3)      | 1.1       | 0.4                | 1.65             | 28               | 25.4 (5.5) | 387.4 (120.8) | 43.9 (19) |
| Terrassa II a   | 72               | 135                | 284          | 72 (9)          | 92     | 41.3 (13)        | 1.3       | 0.25               | 1.03             | 17               | 26.4 (3.9) |
| SEPOCb          | 61               | 318                | 871          | 65 (9)          | 100    | 45 (18.3)        | 1.5       | 38                 | 26.4 (4.2)       |
| Requena II b    | 52               | 186                | 396          | 71 (9)          | 99     | 44.5 (16.5)      | 1         | 0.16               | 0.62             | 17               | 28.1 (5.2) | 380.1 (111.9) |
| ICE COLD ERIC   | 47               | 400                | 1071         | 67 (10)         | 57     | 55.3 (16.9)      | 1.5       | 0.13               | 0.58             | 39               | 26.1 (5.2) |
| PAC-COPD b      | 41               | 342                | 980          | 68 (9)          | 93     | 524 (16.2)       | 1         | 0.04               | 33               | 28.2 (4.7) | 435.5 (90.6) |
| Tenerife b      | 34               | 275                | 653          | 63 (10)         | 79     | 55.8 (12.1)      | 1.2       | 0.06               | 0.37             | 42               | 27.3 (5.1) | 487.4 (87.5) |
| Terrassa III a  | 28               | 66                 | 145          | 72 (9)          | 98     | 30.2 (12.9)      | 1         | 0.42               | 1.81             | 14               | 25.7 (4.3) | 217.7 (76.6) |
| Requena I a     | 23               | 174                | 393          | 72 (9)          | 99     | 48.1 (16.8)      | 1.2       | 0.03               | 0.22             | 23               | 28 (4.2) | 439.4 (125.3) |
| Zaragoza I a    | 21               | 137                | 379          | 66 (8)          | 99     | 498 (17.6)       | 1.1       | 27                 | 27.7 (4.8)       | 44.9 (91.9) |
| Son Espases Mallorca | 17   | 115                | 292          | 70 (7)          | 79     | 41.5 (13.4)      | 1         | 0.59               | 27               | 27.1 (5.9) | 401.5 (81.7) | 16.6 (8.2) |
| Basque b        | 16               | 106                | 299          | 71 (9)          | 98     | 46.9 (11.4)      | 0.6       | 23                 | 26.1 (4.9)       | 44.2 (95.4) |
| Japan           | 15               | 147                | 409          | 69 (7)          | 100    | 47.1 (17.5)      | 0.9       | 22                 | 21 (2.9)         | 36.6 (16.5) |
| La Principesa Madrid | 11   | 318                | 633          | 71 (10)         | 74     | 50 (19.8)        | 1.1       | 0.18               | 0.77             | 19               | 26.2 (5.1) | 337.1 (92.8) |
| Pamplona a      | 7                | 190                | 470          | 65 (8)          | 84     | 68.9 (19.9)      | 1.1       | 37                 | 27.4 (4.4)       | 463.2 (113.9) |
| Mar de Plata Argentina | 3   | 99                 | 147          | 64 (9)          | 60     | 48.8 (18.6)      | 1         | 0.29               | 21               | 27.5 (6.0) | 353.2 (128.7) | 16.1 (7.8) |
| A1ATD d         | 0                | 308                | 834          | 58 (10)         | 60     | 53.1 (25.1)      | 1.2       | 0.52               | 5                | 25.7 (4.9) | 50.8 (19.9) | 20.5 (8.1) |

**Abbreviations:** FEV1% pred. forced expiratory volume in 1 s percentage predicted, mMRC modified Medical Research Council (MMRC) dyspnea scale; past exacerbators are defined as patients with more than one exacerbation in the previous year; mean number previous exacerbations are referred to the previous year, BMI body mass index, 6MWT 6-min walk test, SGRQ Saint George’s Respiratory Questionnaire, CAT COPD Assessment Test

The cohorts are presented in decreasing order of number of events. Most of the variables available provided by the 3CIA collaboration for the different cohorts are shown. In particular, we show all the variables constituting the scores analyzed in our study. We present the standard deviation for all individual variables whose distribution is approximately normal; this is not the case for count (with small numbers) or categorical variables, like number of previous exacerbations or mMRC.

- Cohorts belonging to the Collaborative Cohorts to Assess Multicomponent Indices of COPD in Spain (COCOMICS) collaboration
- Cohorts belonging to the ADO collaboration. For information concerning the cohorts, see [49]
- Since none of the scores could be evaluated in the cohort Requena I (mainly because the variable dyspnea was missing for 95% of the patients, i.e., for 165 out of 174 patients), this cohort was excluded from the analysis
- Since there was no event in a follow-up of 3 years, the cohort A1ATD was excluded from the analysis

Missing cells correspond to variables that are completely missing in the cohort of the correspondent row.
1.0 to 2.8 (the scale goes from 0 to 4, with 4 being the worst), mean number of exacerbations in the previous year (where available) from 0.2 to 1.7, and mean 6-min walk distance (where available) from 218 to 487 m.

MSC meta-analysis of prognostic scores to predict 3-year mortality in patients with COPD

The lower-left part of Table 3 shows all comparisons between the AUCs of the 10 prognostic scores taking into account the correlation among multiple comparisons for the same patients as well as direct and indirect evidence of the entire network (Fig. 1). The median AUC of the GOLD classification of airflow obstruction severity was 0.613 (interquartile range 0.587 to 0.637) and is shown in boldface in the upper-left cell as an anchor to interpret the differences in AUC between the prognostic scores. Compared to GOLD, all prognostic scores showed statistically significantly higher AUCs except for the B-AE-D and GOLD 2011–2016 (cells B1-L1 in Table 3). Compared to the BODE score (the most commonly used prognostic score in COPD, median AUC 0.679 [interquartile range 0.655 to 0.733]), the ADO, updated BODE, and eBODE showed higher AUCs, whereas all other scores performed worse.

Figure 2 shows the comparisons of all scores against the BODE score and that the ADO score and the updated BODE performed better than the other scores (i.e., $AUC_{ADO} - AUC_{BODE} = +0.015$ [95% CI $-0.002$ to $0.032$], $p = 0.08$; $AUC_{BODE} - AUC_{BODE_{updated}} = 0.008$ [95% CI $-0.005$ to $+0.022$]; $p = 0.23$). The sensitivity analysis undertaken excluding from the database the two cohorts used in the large-scale update of the ADO index [15] shows no significant differences.

Heterogeneity, transitivity, and inconsistency

Global heterogeneity was relatively small ($I^2_{pooled} = 0.00011$) (we did not use a $r^2$ for each group ($r^2$) since this is not recommended when there are groups with a single cohort [54]). The groups of the MSC meta-analysis were balanced with regard to characteristics of the different cohorts that may modify the predictive performance of the scores (all a priori defined characteristics that were generating case mix were not statistically significantly different across groups), and we could thus assume transitivity.

The consistency analyses did not suggest local or global inconsistency. Visual analysis of the Q-Q plot and studentized residuals indicated robust local consistency. The likelihood-ratio test statistic showed overall consistency ($Q$ likelihood-ratio test $= 25.29 \equiv \chi^2(0.95, 16) = 26.30$, $p$ value $= 0.06$).

Discussion

Our study has two main findings. Firstly, our results indicate that the ADO index has the best ability to predict 3-year mortality in patients with COPD, followed by the updated BODE and eBODE indices. Given its simplicity, the ADO index may be the most attractive option across care settings to inform patients and health care professionals about prognosis and to inform...
### Table 3: League table presenting the multiple score comparison (MSC) meta-analysis (lower-left half of the table) and the direct random effects meta-analysis (upper-right half of the table)

| Direct meta-analysis | GOLD | B-AE-D | GOLD (2011–2016) | DOSE | BODEx | SAFE | eBODE | BODE | BODE updated | ADO |
|---------------------|------|--------|------------------|------|-------|------|-------|------|--------------|-----|
| MSC meta-analysis   |      |        |                  |      |       |      |       |      |              |     |
|                      | 1    | 2      | 3                | 4    | 5     | 6    | 7     | 8    | 9            | 10  |
| GOLD                | A    | 0.061  | (1st Qu. 0.587, 3rd Qu. 0.637) | 0.005, 0.065 | 0.0017, 0.005, 0.038 | 0.036, 0.008, 0.064 | 0.054, 0.029, 0.079 | 0.047, 0.027, 0.068 | 0.064, 0.004, 0.123 | 0.071, 0.040, 0.102 | 0.080, 0.041, 0.119 | 0.090, 0.072, 0.109 |
| B-AE-D              | B    | 0.010, 0 (−0.010, 0.031) | 0.004, 0.012, 0.039 | NA | 0.009, 0.002, 0.021 | 0.028, 0.017, 0.039 | 0.055, 0.038, 0.072 | 0.047, 0.016, 0.079 | 0.059, 0.046, 0.073 | 0.051, 0.027, 0.076 | 0.067, 0.053, 0.080 |
| GOLD (2011–2016)    | C    | 0.012, 0 (−0.001, 0.024) | 0.001, 0.019, 0.021 | 0.010, −0.005, 0.025 | 0.009, 0.002, 0.021 | 0.028, 0.017, 0.039 | 0.055, 0.038, 0.072 | 0.047, 0.016, 0.079 | 0.059, 0.046, 0.073 | 0.051, 0.027, 0.076 | 0.067, 0.053, 0.080 |
| DOSE                | D    | 0.022, 0.006, 0.037 | 0.011, 0.007, 0.029 | 0.010, −0.005, 0.025 | 0.018, 0.008, 0.029 | NA | 0.039, 0.007, 0.070 | 0.033, 0.000, 0.065 | 0.043, 0.002, 0.088 | 0.061, 0.044, 0.079 |
| BODEx               | E    | 0.041, 0.027, 0.055 | 0.030, 0.014, 0.047 | 0.029, 0.015, 0.043 | 0.019, 0.005, 0.033 | NA | 0.030, 0.001, 0.061 | 0.031, 0.017, 0.079 | 0.039, 0.028, 0.105 | 0.050, 0.034, 0.066 |
| SAFE                | F    | 0.061, 0.034, 0.087 | 0.050, 0.018, 0.082 | 0.049, 0.022, 0.076 | 0.039, 0.010, 0.068 | 0.020, 0.009, 0.048 | NA | 0.011, 0.000, 0.023 | 0.005, 0.009, 0.018 | 0.007, 0.007, 0.015 |
| eBODE               | G    | 0.065, 0.046, 0.085 | 0.055, 0.032, 0.078 | 0.054, 0.034, 0.074 | 0.044, 0.023, 0.064 | 0.024, 0.007, 0.042 | 0.005, −0.025, −0.035 | −0.001, −0.020, −0.017 | 0.002, −0.031, 0.034 | 0.024, −0.018, 0.066 |
| BODE                | H    | 0.068, 0.052, 0.084 | 0.057, 0.034, 0.080 | 0.056, 0.039, 0.074 | 0.046, −0.027, −0.065 | 0.027, 0.009, 0.045 | 0.007, −0.019, 0.034 | 0.003, −0.016, 0.021 | 0.005, −0.006, 0.017 | −0.004, −0.023, 0.016 |
| BODE upd.           | I    | 0.076, 0.058, 0.095 | 0.066, 0.041, 0.091 | 0.065, 0.045, 0.085 | 0.055, −0.033, −0.076 | 0.036, 0.015, 0.056 | 0.016, −0.012, 0.043 | 0.011, −0.009, 0.031 | 0.008, −0.005, 0.022 | −0.005, −0.032, 0.022 |
| ADO                 | L    | 0.083, 0.070, 0.096 | 0.072, 0.052, 0.093 | 0.071, 0.056, 0.087 | 0.070, −0.052, −0.089 | 0.042, 0.026, 0.058 | 0.022, −0.005, 0.038 | 0.018, −0.003, 0.038 | 0.015, −0.002, 0.032 | 0.007, −0.012, 0.026 |

Abbreviations: AUC area under the curve; the lower-left half of the table refers to the MSC meta-analysis. The upper-right half of the table refers to direct comparisons using conventional random effects meta-analysis. The first cell (first row, first column) gives a reference value (in boldface), namely the median and 1st and 3rd quartiles of the AUC of the GOLD classification across cohorts as an anchor to interpret the differences in the score in the row and the score in the column; instead, for the upper-right half of the table we report the difference between the AUCs of the score in the row and the score in the column; instead, for the upper-right half of the table we report the difference between the AUCs of the score in the row and the score in the column.
treatment decisions whose effectiveness may depend on life expectancy. Secondly, we presented a comprehensive approach for external validation and concurrent comparison of prognostic scores and its first application. MSC meta-analysis is a method adapted from network meta-analysis that meets the call for new approaches for external validation and concurrent comparison of risk prediction models and scores that should take advantage of data sharing, individual patient data (IPD), and advanced analytical techniques [36, 37, 45, 64, 65].

In practice, the GOLD score using just lung function is still used most commonly to grade disease severity, which is traditionally related to prognosis as in other fields (e.g.,

---

**Fig. 1** Network plot. Network representing which prognostic scores belong to the different groups. Each node represents a score and each closed polygon represents a group of cohorts where the same prognostic scores are available. The thickness of the lines represents the total number of deaths in the specific group.

**Fig. 2** Comparison of AUC of prognostic scores. Difference in AUC (shown with confidence interval with 95% confidence level) among the different scores and the BODE index (chosen here as the reference score) in the MSC meta-analysis. As a reference we use the median of the AUC of the BODE score 0.679 (1st Qu. 0.655, 3rd Qu. 0.733)
cancer). FEV1% pred. (thus, GOLD classification) is an important parameter at the population level in the prediction of important clinical outcomes such as mortality and hospitalization. The revised combined COPD assessment and their further developments integrate the severity of airflow limitation assessment, also providing information regarding symptom burden and risk of exacerbation [51]. However, the results of our analysis show that, when the aim is to predict mortality in individuals, other scores such as ADO, updated BODE, and eBODE are substantially better than the GOLD classifications (in our analysis, GOLD and GOLD 2011–2016). We note that the AUC for the best score (ADO) is 0.69, a moderately good discriminative performance; however, we can often not expect a much higher discriminative performance in clinical settings (for instance, see [31]).

The predictive performance of a prognostic score is important, but it is not the only criterion for choosing a prognostic score for practice. Indeed, with an eye towards applicability, the time, cost, and burden for patients and practitioners to measure the predictors of a prognostic score should be taken into consideration [66]. We deem a prognostic score such as ADO to be easily available if it only includes simple questions, easily available information from medical charts, and spirometry (performed for the diagnosis of COPD) [50, 51].

Scores to predict mortality are also useful beyond estimating prognosis. Nowadays, no treatments to lower the risk of mortality are currently available for patients with COPD; thus, for this outcome, prediction scores cannot provide risk-stratified treatment guidance. However, prognostic scores may help to make randomized trials with all-cause mortality as primary outcome more efficient than previous trials by only including patients at higher risk [67]. Also, prognostic scores for all-cause mortality are particularly attractive for multimorbid patients such as COPD patients, where cardiovascular disease, diabetes, renal disease, and lung cancer, among other conditions, also contribute to mortality [68, 69]. Patients with COPD often receive less than optimal prevention and treatment of cardiovascular disease, which may partly reflect a therapeutic nihilism. Of course, there are patients who are unlikely to benefit from long-term cardiovascular prevention because of short life expectancy. However, a prognostic score provides a better basis for decisions on cardiovascular prevention, lung cancer screening, or other treatments and may limit under- and over-treatment in COPD [1, 70, 71].

Many prognostic models and scores (as in the models’ simplified forms) are never validated in practice, and many investigators develop a second model instead of relying on existing scores at least as a starting point. Such practice has led to numerous prognostic scores for the same conditions that are left without external validation. Thus, we introduced MSC meta-analysis, which addresses the lack of external validation and comparisons of prognostic scores by comparing their predictive performance in external validation cohorts and simultaneously considering the entire network of direct and indirect comparisons. Thereby, it allows for a comparison of predictive performance that is not limited by non-comparable spectrum of populations, as is commonly the case when evaluating the results of independent validation studies. MSC meta-analysis can be applied to any medical field, with the availability of individual patient data being the only major limiting factor.

Strengths of our study include the careful analytical approach to MSC meta-analysis and the availability of the R code, which allows for widespread use and potential further development of the method. For the particular application of MSC meta-analysis here, a major strength is the large high-quality database of the 3CIA collaboration with the broadest possible COPD patient spectrum. The diverse case mix and broad patient spectrum greatly increase the probability that our results are generalizable to all COPD patients. A limitation of the study is that, ideally, a network meta-analysis is conducted prospectively and jointly planned for all of the cohorts involved to ensure equality of the clinical settings and homogeneity of study design, conduct, and variable definitions, though this will rarely be the case in reality. Another limitation of our analysis is that we only used AUC as a performance measure, which we did for theoretical and practical reasons [43]. In general, improvements in AUC have to be interpreted with caution [72]. Furthermore, we cannot exclude the possibility of case-mix effects due to variables that were not available in the database or unknown.

Further research needs include the extension of MSC to include measures of calibration, which is arguably as important as discrimination. For the area of COPD, it would be attractive to apply MSC to risk scores for exacerbations [51, 73]. However, there are likely too few thoroughly developed and externally validated scores to predict exacerbations in patients with COPD [31]. Finally, given the large number of risk scores in the medical field and the lack of external validations and comparisons of risk scores, there is a great need for comparative studies that may use MSC in order to inform clinical practice and research about the most predictive scores [31].

Conclusions

Borrowing from network meta-analysis, we presented a comprehensive approach for external validation and concurrent comparison of multiple prognostic scores. While our analyses showed best performance for the ADO and updated BODE scores to predict mortality for patients with COPD, MSC meta-analysis can be applied
to prognostic scores in any medical field to identify the best scores, possibly paving the way for stratified medicine, public health, and research.

**Additional files**

**Additional file 1:** The Appendix. (DOCX 90 kb)

**Abbreviations**

ADO: Age, dyspnea, airflow obstruction; AUC: Area under the curve; B-AE-D: Body mass index, acute exacerbations, dyspnea; BODE: Body mass index, airflow obstruction, dyspnea and severe exacerbations; BODEi: Body mass index, airflow obstruction, dyspnea, severe acute exacerbation of COPD; COPD: Chronic obstructive pulmonary disease; DOSE: Dyspnea, obstruction, smoking and exacerbation frequency; e-BODE: Severe acute exacerbation of COPD plus BODE; GOLD: Global Initiative for Chronic Obstructive Lung Disease; MSC: Multiple score exacerbation frequency; sGRQ: Severe acute exacerbation of COPD plus BODE; SGRQ: St. George’s Respiratory Questionnaire; SGRQ: Surface under the cumulative ranking curve

**Acknowledgements**

We would like to thank Sarah Crook, Violeta Gaveikaite, Laura Werlen, and Alex Marzel (all from the University of Zurich, Zurich, Switzerland) for their comments. We also thank the reviewers for their valuable comments.

**Funding**

MAP obtained funding for the current study. All authors organized funding for their respective cohorts, which has been described in detail elsewhere [49].

**Availability of data and materials**

The datasets supporting the conclusions of this article are reported within a previous article [49]. The programming language used for the main analysis was R version 3.0.2.

**Authors’ contributions**

All the authors had full access to all of the data in the study and take responsibility for the integrity of the data. BG, SRH, and MAP designed the manuscript. All authors provided a critical revision of the manuscript for important intellectual contribution. BG, SRH, and MAP provided necessary support to contribute their data to the 3CIA collaboration. JBS and MAP supervised the study. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

All cohorts were approved by ethics committees, and the participants gave consent to participate approved the final manuscript.

**Consent for publication**

Not applicable.

**Competition of interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 2. Department of Pulmonary Medicine, Paracelsus Medizinische Privatuniversitat, Salzburg, Austria. 3. Hospital Universitario de Valme, Sevilla, Spain. 4. Internal Medicine, Hospital Universitario Mutua de Terrassa, Terrassa, Spain. 5. Pulmonary Department and Research Unit, Hospital Universitario NS La Candelaria, Tenerife, Spain. 6. Network and Health Services Research Chronic Diseases (REDISSEC), Hospital Galdakao, Bilzkaia, Spain. 7. Servicio de Neumología, Hospital Universitario Arnau de Vilanova, Lleida, Spain. 8. Pulmonary Department, Clínica Universitaria de Navarra, Pamplona, Spain. 9. European Respiratory Society (ERS) Guidelines Director, Barcelona, Spain. 10. Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, MA, USA. 11. Instituto de Investigación Sanitaria Princesa (ISP)-Servicio de Neumología- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain. 12. Global, CIBER Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra (UPF), Barcelona, Spain. 13. Global, Centre for Research in Environmental Epidemiology (CREAL), IIMH (Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 14. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 15. Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA. 16. Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. 17. Centre for Clinical Documentation and Evaluation, Northern Norway Regional Health Authority, Bodø, Norway. 18. University of Bergen, Haukeland University Hospital, Bergen, Norway. 19. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 20. Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 21. Department of Respiratory Medicine, Hospital Son Espases-IDSilBa-CIBERES, Palma de Mallorca, Spain. 22. Instituto de Investigación Sanitaria Princesa (ISP)-Servicio de Neumología- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain. 23. University Nacional de la Plata, Hospital San Juan de Dios de La Plata, Buenos Aires, Argentina. 24. Hopitaux Universitaires Paris Centre, Service de Pneumologie AP-HP, Paris, France. 25. Hospital Cochin; Université Paris Descartes, Paris, France. 26. University of British Columbia, James Hogg Research Centre, Vancouver, Canada. 27. Instituto de Investigación del Hospital Universitario de la Princesa (ISP), Universidad Autónoma de Madrid, Servicio de Neumología, Madrid, Spain. 28. Scientific and Methodological Consultant of SEPAR www.separ.es, Barcelona, Spain. 29. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland. 30. Room HRS G29, CH -8001 Zürich Switzerland. 31. Epidemiology & Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Received: 14 August 2017 Accepted: 26 January 2018

**Published online:** 02 March 2018

**References**

1. Steyerberg EW. Clinical prediction models. In: Gail M, Krickeberg K, Sarne J, Tsiatis A, Wong W, editors. Statistics for Biology and Health. Berlin: Springer; 2010. ISBN: 978-1-4419-2648-7.
2. Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research 1: what, why, and how? BMJ. 2009;338:1117–20.
3. Steyerberg EW, Moons KGM, Van Der Windt DA, Hayden JA, Perel P, Schotman P, et al. Prognosis Research Strategy (PROGRESS): 3. prognostic model research. PLoS Med. 2013;10(9).
4. Harrell FE. Regression modelling strategies. In: Bickel P, Diggle P, Feinberg SE, editors. Statistics for Biology and Health. Berlin: Springer; 2015. ISBN: 978-3-19-194244-0.
5. Laupacis A, Wells G, Richardson WS, Tugwell P. Users’ guides to the medical literature: V. How to use an article about prognosis. JAMA. 1994;272:234–7.
6. Puhan MA, Yu T, Stegeman I, Varadhan R, Singh S, Boyd CM. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med. 2015;13:11.
7. Hayes DF, Markus HS, Leslie RD, Topol ER. Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med. 2014;12:8.
8. Yu T, Vollenweider D, Varadhan R, Li T, Boyd C, Puhan MA. Support of personalized medicine through risk-stratified treatment
recommendations — an environmental scan of clinical practice guidelines. BMC Med. 2013;11:7.

9. Nickel CH, Bingisser R, Morganthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10:7.

10. Voung K, McGeechan K, Armstrong BK, Cust AE. Risk prediction models for incident primary cutaneous melanoma: a systematic review. JAMA Dermatology. 2014;150:434.

11. Kagen D, Theobald C, Freeman M. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306:1688–98.

12. Youman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults; a systematic review. JAMA. 2012;307:182–92.

13. Collins GS, Mallett S, Omar O, Yu L-M. Developing risk prediction models for type 2 diabetes; a systematic review of methodology and reporting. BMC Med. 2011;19:14.

14. Damien JAAG, Hoof l, Schult E, Debray TPA, Collins GS, Tzoulaki I, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i1.

15. Puhan MA, Hansel NN, Sarabradiol P, Enright P, Lange P, Hickson D, et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open. 2012;2:1–10.

16. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí A, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;373:704–11.

17. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.

18. Soler-Cataluña JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103:692–9.

19. Esteban C, Quintana JM, Aburto M, Moraza J, Arostegui I, Espana PP, et al. The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. Respir Med. 2011;105:1662–70.

20. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med. 2008;168:79–1.

21. Schenbri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009;103:1461–7.

22. Esteban C, Quintana JM, Aburto M, Moraza J, Capelastegui I, Umana PP, et al. The ADO and BODE indices. Eur Respir J. 2012;39:1655–44.

23. Escher MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, et al. Development and validation of a survey-based COPD severity score. Chest. 2005;127:1890–7.

24. Cardoso F, Tufanin AT, Cozzolli C, Mursu JK. Replacement of the 6-min walk test with maximal oxygen consumption in the BODE index applied to patients with COPD: an equivalence study. Chest. 2007;132:477–82.

25. Williams JEA, Green RH, Warington V, Steiner MC, Morgan MDL, Singh SJ. Development of the i-BODE: validation of the incremental shuttle walking test within the BODE index. Respir Med. 2012;106:390–6.

26. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180:1189–95.

27. Azariraman MS, Faizzi FA, Faisal MP, Azam Z, Rosina AM, Roslan H. The SAFE (SGOR score, airflow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J. 2007;83:492–7.

28. Esteban C, Quintana JM, Moraza J, Aburto M, Aguiri U, Agüirre-Aguirre J, et al. BODE-Index vs HADO-score in chronic obstructive pulmonary disease: which one to use in general practice? BMC Med. 2010;8:28.

29. Quintana JM, Esteban C, Urrozrunzaga A, Garcia-Gutierrez S, Gonzalez N, Barrio I, et al. Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments. BMC Med. 2014;12:66.
57. Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:j3511.

58. Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ. Accounting for correlation in network meta-analysis with multi-arm trials. Res Synth Methods. 2012;3:142–60.

59. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–71.

60. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:9.

61. Ransohoff DF, Feinstein A. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926–30.

62. Vergouwe Y, Moons KGM, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172:971–80.

63. Debray TPA, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KGM. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68:279–89.

64. Debray TPA, Riley RD, Rovers MM, Reitsma JB, Moons KGM. Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use. PLoS Med. 2015;12:1–12.

65. Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM. Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol. 2014;179:621–32.

66. Ioannidis JP, Tzoulaki I. What makes a good predictor? The evidence applied to coronary artery calcium score. JAMA. 2010;303:1646–7.

67. Vestbo J, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–26.

68. Fabbri LM, Luppi F, Beghè B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.

69. Divo M, Cote C, De Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155–61.

70. Reilly BM, Evans AT, Schaider JJ, Das K, Calvin JE, Moran LA, et al. Impact of a clinical decision rule in the emergency department. JAMA. 2002;288:342–50.

71. McGinn TG, Guyatt GH, Wyer PC, David Naylor C, Stiell IG, Richardson WS. Users’ guides to the medical literature. JAMA. 2000;284:79–84.

72. Tzoulaki I, Liberopoulos G, Ioannidis JPA. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345–52.

73. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:10.